US 11,667,704 B2
Anti-IL-17 antibody/TNFR ECD fusion protein and use thereof
Pinliang Hu, Beijing (CN); Jing Zou, Beijing (CN); Weidong Hong, Beijing (CN); Yun He, Beijing (CN); Jie Bai, Beijing (CN); Lingyun Song, Beijing (CN); Wendi Yang, Beijing (CN); Zhijian Lv, Hangzhou (CN); and Shaoyun Xiang, Hangzhou (CN)
Assigned to BEIJING BEYOND BIOTECHNOLOGY CO., LTD, Beijing (CN); and HANGZHOU POLYMED BIOPHARMACEUTICALS, INC., Hangzhou (CN)
Appl. No. 16/764,788
Filed by BEIJING BEYOND BIOTECHNOLOGY CO., LTD, Beijing (CN); and HANGZHOU POLYMED BIOPHARMACEUTICALS, INC., Zhejiang (CN)
PCT Filed Nov. 6, 2018, PCT No. PCT/CN2018/114079
§ 371(c)(1), (2) Date May 15, 2020,
PCT Pub. No. WO2019/096026, PCT Pub. Date May 23, 2019.
Claims priority of application No. 201711137039.8 (CN), filed on Nov. 16, 2017.
Prior Publication US 2021/0261654 A1, Aug. 26, 2021
Int. Cl. C07K 16/46 (2006.01); C07K 14/00 (2006.01); A61K 39/00 (2006.01); C12N 15/00 (2006.01); C07K 16/24 (2006.01); A61P 29/00 (2006.01); C12N 15/52 (2006.01)
CPC C07K 16/244 (2013.01) [A61P 29/00 (2018.01); C12N 15/52 (2013.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01)] 2 Claims
 
1. A fusion protein of an anti-IL-17 antibody and TNFR,
wherein the fusion protein comprises or consists of
(1) the first subunit of SEQ ID NO: 68 and the second subunit of SEQ ID NO: 70; or
(2) the first subunit of SEQ ID NO: 74 and the second subunit of SEQ ID NO: 72.